MEDP

MEDP

USD

Medpace Holdings Inc. Common Stock

$594.530+8.583 (1.465%)

Real-time Price

Healthcare
Diagnostics & Research
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$585.947

High

$599.990

Low

$580.451

Volume

0.05M

Company Fundamentals

Market Cap

16.7B

Industry

Diagnostics & Research

Country

United States

Trading Stats

Avg Volume

0.34M

Exchange

NMS

Currency

USD

52-Week Range

Low $250.05Current $594.530High $625

Related News

Reuters

Indian pharmacy retailer MedPlus profit jumps with store opening push

Medplus Health Services , one of India's top retail pharmacy chains, reported a 43.3% rise in second-quarter profit on Friday, driven by higher sales from new store openings and steady demand for its private label products.

View more
Indian pharmacy retailer MedPlus profit jumps with store opening push
Analyst Upgrades

TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462

TD Cowen analyst Charles Rhyee maintains Medpace Hldgs with a Sell and raises the price target from $356 to $462.

View more
TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462
Analyst Upgrades

Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485

Barclays analyst Luke Sergott maintains Medpace Hldgs with a Underweight and raises the price target from $425 to $485.

View more
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485
Analyst Upgrades

Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655

Mizuho analyst Ann Hynes maintains Medpace Hldgs with a Outperform and raises the price target from $575 to $655.

View more
Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655
Analyst Upgrades

Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins

Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance.

View more
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
BusinessWire

Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Revenue of $659.9 million in the third quarter of 2025 increased 23.7% from revenue of $533.3 million for the comparable prior-year period, representing a backlog conversion rate of 23.0%. Net new business awards